This article reports on the company’s own public disclosures and press coverage; it is not investment advice, and GSN did not independently verify claims made by the company beyond the linked source.
Microbot Medical Inc. (Nasdaq: MBOT), a small, commercial-stage surgical robotics company, said it recorded growth of more than 100% quarter over quarter in both revenue and new customers for the second quarter of 2026, the three months ended June 30, compared with the first quarter of the year. According to the company’s announcement, published July 7, 2026 via GlobeNewswire, the growth was tied to its LIBERTY Endovascular Robotic System, whose full commercial launch began April 13, 2026.
Microbot Medical describes itself, in the company’s own public materials, as a commercial-stage medical device company focused on transforming endovascular procedures through advanced robotic technology. The company describes its LIBERTY Endovascular Robotic System as the first single-use, remotely operated robotic solution designed for precision, efficiency and safety, and it says that system, backed by its intellectual property portfolio and what it calls a commitment to innovation, is meant to drive the future of endovascular care. Measured against that stated aim, the quarter’s disclosures, the revenue and customer growth, the new hospital adoptions, the federal supply agreement and the system’s first clearance outside the United States, represent, according to the company, a widening of the commercial and clinical footprint through which it says it intends to pursue that goal.
The company said new hospitals adopted the LIBERTY system during the second quarter in Massachusetts, North Carolina, Michigan and Pennsylvania. Microbot Medical also reported that its sales territory coverage expanded from four to eight during the quarter, and it stated a goal of reaching 12 territories by the end of the year.
In a separate development disclosed in the same announcement, Microbot Medical said it signed an agreement with Lovell Government Services to supply the LIBERTY system to federal healthcare systems, including the Department of Veterans Affairs and the Military Health System.
The company additionally said it received its first marketing clearance for the LIBERTY system outside the United States, granted by Israel’s Ministry of Health. Microbot Medical also said it established an agreement for a second manufacturing site for the system.
Taken together, the results and disclosures cover a range of commercial and regulatory milestones for the company in the second quarter, spanning hospital-level adoption in four states, an expansion of the company’s direct sales footprint, a new agreement aimed at federal healthcare purchasers, and the company’s first regulatory clearance in a market outside the United States. The LIBERTY system’s full commercial launch, which the company said began April 13, 2026, fell within the second quarter, and the more-than-100% quarter-over-quarter growth figures reported by the company are measured against the first quarter of 2026, the period immediately preceding that launch date.
Microbot Medical framed the quarter’s results, including the revenue and customer growth figures, the four new state hospital adoptions, the sales territory expansion, the Lovell Government Services agreement, the Israel Ministry of Health clearance, and the second manufacturing site agreement, as the substance of its July 7 announcement. GSN is reporting the figures and developments as disclosed by the company and has not independently verified them beyond the linked GlobeNewswire source.
